Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Denali TherapeuticsSTU:4DN +4.78%39 Dividend Payout Ratio is 0.00 as of Jun. 2026. GuruFocus rates STU:4DN with a GF Score™ of 39/100 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 131 Biotechnology companies, Denali Therapeutics ranks worse than 763358.02% on this metric.
The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period. Denali Therapeutics's Dividend Payout Ratio for the
months ended in Jun. 2026 was 0.00.
The historical rank and industry rank for Denali Therapeutics's Dividend Payout Ratio or its related term are showing as below:
STU:4DN's Dividend Payout Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 0.46 * Ranked among companies with meaningful Dividend Payout Ratio only.
Denali Therapeutics (STU:4DN) Dividend Payout Ratio Explanation
In dividends investing, Dividend Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Denali Therapeutics Dividend Payout Ratio Related Terms
Denali Therapeutics Dividend Payout Ratio Historical Data
* Premium members only.
The historical data trend for Denali Therapeutics's Dividend Payout Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:4DN vs RCUS, ALMS, ELVN: Dividend Payout Ratio Comparison
For the Biotechnology subindustry, Denali Therapeutics's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Denali Therapeutics Dividend Payout Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Denali Therapeutics's Dividend Payout Ratio distribution charts can be found below:
* The bar in red indicates where Denali Therapeutics's Dividend Payout Ratio falls into.
Denali Therapeutics Dividend Payout Ratio Calculation
The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period.
Denali Therapeutics's Dividend Payout Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Denali Therapeutics (STU:4DN) has a Dividend Payout Ratio of 0.00 as of Jun. 2026. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on Denali Therapeutics and its competitors. According to the industry distribution chart, Denali Therapeutics ranks #999999 out of 131 companies in the Biotechnology industry.
Is Denali Therapeutics' Dividend Payout Ratio too high?
Denali Therapeutics' current Dividend Payout Ratio is 0.00. Based on the distribution chart, Denali Therapeutics ranks #999999 out of 131 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Denali Therapeutics has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Denali Therapeutics' Dividend Payout Ratio compare to RCUS and ALMS?
According to the Biotechnology industry distribution chart, Denali Therapeutics ranks #999999 out of 131 companies for Dividend Payout Ratio. This places Denali Therapeutics in the lower half of its industry. The industry median Dividend Payout Ratio is 0.46. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Payout Ratio for a Biotechnology company?
The median Dividend Payout Ratio among Biotechnology companies is 0.46, based on 131 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Payout Ratio significantly above this median, while those in the bottom quartile fall well below. However, Dividend Payout Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Payout Ratio mean?
A high Dividend Payout Ratio can signal that a stock is expensive relative to its fundamentals. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on Denali Therapeutics and its competitors. For the Biotechnology industry, the median Dividend Payout Ratio is 0.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Denali Therapeutics's current Dividend Payout Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Denali Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Denali Therapeutics (STU:4DN) is currently considered Significantly Overvalued. The current Dividend Payout Ratio is 0.00. Denali Therapeutics' overall GF Score™ is 39/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Payout Ratio calculated?
Dividend Payout Ratio is calculated from a company's financial statements. For Denali Therapeutics (STU:4DN), the current Dividend Payout Ratio is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.
39GF Score
Get the complete analysis for STU:4DN
Dividend Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:4DN has been successfully added to your 
